Clinical Trial Update: A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating immunogenicity and safety of a whole-cell pertussis–containing vaccine given with Rotarix or RotaTeq has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Pertussis
• Rotavirus Gastroenteritis
• Tetanus

Drugs mentioned

• RotaTeq (rotavirus vaccine, pentavalent)
• Rotarix (Rotavirus vaccine (live attenuated))
• Whole-cell pertussis-containing vaccine (pertussis vaccine, inactivated)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Rotavirus Gastroenteritis, Diphtheria | Phase 3 | Status: WITHDRAWN